In ₹ Crore except Per Share Latest Annual	CAPLIPOINT FY26	AJANTPHARM FY26	ERIS FY26	GLAND FY26	Peer Average
Valuation — at last close
P/E	28.17×	40.93×	◆ 25.67×	49.31×	38.64× -27%
P/B	5.04×	9.58×	◆ 4.13×	4.89×	6.20× -19%
EV/EBITDA	22.47×	30.77×	◆ 16.38×	29.17×	25.44× -12%
Market Cap	₹18,058 Cr	₹43,367 Cr	₹16,116 Cr	₹50,655 Cr	₹36,713 Cr -51%
Growth
Revenue CAGR 3Y	14.25%	13.37%	◆ 22.92%	21.06%	19.12% -25%
Revenue CAGR 5Y	15.56%	13.54%	◆ 20.89%	13.18%	15.87% -2%
Net Income CAGR 3Y	19.89%	◆ 21.55%	20.06%	9.57%	17.06% +17%
Revenue YoY (latest Q)	19.63%	◆ 32.53%	12.61%	19.57%	21.57% -9%
Net Income YoY (latest Q)	18.79%	◆ 49.18%	39.17%	47.09%	45.15% -58%
Profitability
EBITDA Margin	34.79%	25.58%	◆ 35.79%	25.34%	28.90% +20%
Net Income Margin	◆ 29.71%	19.37%	20.69%	15.98%	18.68% +59%
Return on Common Equity	19.92%	◆ 25.39%	18.34%	10.53%	18.09% +10%
Return on Capital Employed	20.97%	◆ 27.90%	15.37%	11.73%	18.33% +14%
Return on Assets	17.91%	◆ 18.91%	8.99%	8.66%	12.19% +47%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.05×	0.59×	0.02×	0.22× -100%
Interest Coverage	◆ 790.90×	75.83×	4.36×	36.24×	38.81× +1938%
Scale — latest FY
Revenue / Total Income	₹2,187 Cr	₹5,453 Cr	₹3,129 Cr	₹6,431 Cr	₹5,004 Cr -56%
Net Income	₹650 Cr	₹1,056 Cr	₹648 Cr	₹1,027 Cr	₹910 Cr -29%
Total Assets	₹4,045 Cr	₹6,155 Cr	₹7,366 Cr	₹12,511 Cr	₹8,677 Cr -53%
EPS	₹84.36	₹84.53	₹45.33	₹62.35	₹64.07 +32%
Book Value per Share	₹471.9	₹361.16	₹281.78	₹628.67	₹423.87 +11%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.